Galaxy Therapeutics, a privately held, clinical-stage medical device company focused on treating brain aneurysms, announced the official opening of its new 9,200 square foot (855 m²) facility designed to support the company's transition toward commercial readiness and global distribution.
The newly inaugurated facility includes two ISO Class 7 Controlled Environment Rooms (CERs) totaling 2,400 square feet (223 m²), with one room measuring 1,000 square feet (93 m²) and the other 1,400 square feet (130 m²). In addition, the site features 1,500 square feet (139 m²) of dedicated R&D and manufacturing space, as well as ground-level roll-up doors to streamline shipping and receiving logistics.
This expansion positions Galaxy to scale production, accelerate time-to-market, and provide global support for patients and clinical partners.
"This new facility reflects our readiness to scale and deliver excellence for every patient we serve," said Jim Twitchell, Chief Operating Officer of Galaxy Therapeutics.
"This milestone brings us closer to making transformative care a global reality," added Dr. Sam Zaidat, President and CEO.
Comments powered by CComment